Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 3/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 9/20 | 0.37 |
| ▸ | NR1H3 | Q13133 | 9/20 | 0.37 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.35 |
| ▸ | KHK | P50053 | 1/20 | 0.35 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.34 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5850558 | 1.00 | AKT1 (0.39) | AKT1NR1H2NR1H3DDB1CRBN | |
| SCHEMBL5851082 | 1.00 | AKT1 (0.39) | AKT1NR1H2NR1H3DDB1CRBN | |
| SCHEMBL5849085 | 0.81 | AKT1 (0.47) | AKT1KHKCHRNB1CHRNB2CHRNB4 | |
| SCHEMBL5848897 | 0.81 | AKT1 (0.47) | AKT1KHKCHRNB1CHRNB2CHRNB4 | |
| SCHEMBL5848903 | 0.81 | AKT1 (0.47) | AKT1KHKCHRNB1CHRNB2CHRNB4 | |
| SCHEMBL5849340 | 0.80 | AKT1 (0.45) | AKT1KHKCHRNB1CHRNB2CHRNB4 | |
| SCHEMBL5849329 | 0.80 | AKT1 (0.45) | AKT1KHKCHRNB1CHRNB2CHRNB4 | |
| SCHEMBL5850636 | 0.80 | AKT1 (0.45) | AKT1KHKCHRNB1CHRNB2CHRNB4 | |
| SCHEMBL5849534 | 0.78 | SMN1; SMN2 (0.42) | AKT1 | |
| SCHEMBL5849062 | 0.78 | SMN1; SMN2 (0.42) | AKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7101896-B2 | Pharmaceutical compositions and methods for use | TARGACEPT, INC. (US) | 2006-09-05 | — | — | US | disclosed |
| US-20050267111-A1 | Pharmaceutical compositions and methods for use | DULL GARY M | 2005-12-01 | — | — | US | disclosed |
| US-6890935-B2 | Pharmaceutical compositions and methods for use | TARGACEPT, INC. (US) | 2005-05-10 | — | — | US | disclosed |
| WO-2002088114-A2 | HETEROARYL OFEFINIC AZACYCLIC AND HETEROARYL ACETYLENIC AZACYCLIC COMPOUNDS FOR THE TREATMENT OF CNS DISORDERS | TARGACEPT, INC. (US) | 2002-11-07 | — | — | WO | disclosed |
| US-20020058652-A1 | Pharmaceutical compositions and methods for use | TARGACEPT, INC. | 2002-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267111-A1 | Pharmaceutical compositions and methods for use | CYP3A7, AADAC, CYP2B6 | AKT1 3325/4885NR1H2 1207/4885NR1H3 858/4885 |
| US-20020058652-A1 | Pharmaceutical compositions and methods for use | CYP3A7, AADAC, CYP2B6 | AKT1 3325/4885NR1H2 1207/4885NR1H3 858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.